v3.26.3
Segment information (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting
The following table presents the Company's segment significant expenses regularly reviewed by the CODM and net loss for the three and nine months ended September 30, 2026:
Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)20262026
Operating expenses:
Research and development:
Clinical and external research and development costs$4,339 $9,444 
Personnel related838 1,890 
Other100 127 
General and administrative costs
Personnel related1,452 2,793 
Professional fees1,547 3,397 
Other*2,467 2,649 
Total operating expenses10,743 20,300 
Operating loss(10,743)(20,300)
Other income/(expenses):
Interest income925 1,225 
Other income, net94 94 
Total other income, net1,019 1,319 
Net loss$(9,724)$(18,981)

*Includes Merger-related expenses